Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key

Clinical Infectious Diseases

Volumn 62, Issue , 2016, Pages S238-S243

  Van Cutsem, Gilles ^a,b   Isaakidis, Petros ^a   Farley, Jason ^c   Nardell, Ed ^d   Volchenkov, Grigory ^e   Cox, Helen ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF NURSING   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Vladimir Oblast Tuberculosis Dispensary ^*  (Russian Federation)

Author keywords

community; diagnosis; infection control; multidrug resistant tuberculosis; treatment

Indexed keywords

ARTICLE; AWARENESS; DISEASE TRANSMISSION; EARLY DIAGNOSIS; FEAR; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HOSPITAL MANAGEMENT; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT ISOLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; QUALITY CONTROL; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; INFECTION CONTROL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; EARLY DIAGNOSIS; HUMANS; INFECTION CONTROL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84965010303     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw012     Document Type: Article

References (68)

1. Reichman LB, Tanne JH. Timebomb: The global epidemic of multi-drug resistant tuberculosis. New York: McGraw-Hill, 2001.
2. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: WHO, 2014.
3. Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazidresistant variants of tubercle bacilli. Science 1953; 118:297-9.
4. World Health Organization. Guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: WHO, 1996.
5. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3:13-21.
6. Coker R. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? Int J Tuberc Lung Dis 2002; 6:649-50.
7. Zhao M, Li X, Xu P, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One 2009; 4:e4370.
8. Moodley P, Shah NS, Tayob N, et al. Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. PLoS One 2011; 6:e17513.
9. Gumusboga A, Aung KJM, Rigouts L, Van Deun A. Transmission of multidrugresistant and extensively drug-resistant tuberculosis in rural Bangladesh: lessons learnt. Public Health Action 2012; 2:76-8.
10. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low-and middle-income countries: a systematic review. PLoS Med 2006; 3:e494.
11. Tudor C, Van der Walt M, Margot B, et al. Tuberculosis among health care workers in KwaZulu-Natal, South Africa: a retrospective cohort analysis. BMC Public Health 2014; 14:891.
12. Jarand J, Shean K, O'Donnell M, et al. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health 2010; 15:1179-84.
13. O'Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010; 153:516-22.
14. Gandhi NR,Weissman D, Moodley P, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis 2013; 207:9-17.
15. Wenger PN, Otten J, Breeden A, Orfas D, Beck-Sague CM, Jarvis WR. Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995; 345:235-40.
16. Cox HS, Sibilia K, Feuerriegel S, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359:2398-400.
17. Gelmanova IY, Keshavjee S, Golubchikova VT, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85:703-11.
18. Isaakidis P, Das M, Kumar AM, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. PLoS One 2014; 9: e110461.
19. World Health Organization. Framework for effective tuberculosis control. Report No. WHO/TB/94.179. Geneva, Switzerland: WHO Tuberculosis Programme, 1994.
20. Escombe AR, Huaroto L, Ticona E, et al. Tuberculosis transmission risk and infection control in a hospital emergency department in Lima, Peru. Int J Tuberc Lung Dis 2010; 14:1120-6.
21. Dharmadhikari AS, Mphahlele M, Venter K, et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2014; 18:1019-25.
22. Barrera E, Livchits V, Nardell E. F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy. Int J Tuberc Lung Dis 2015; 19:381-4.
23. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010; 14:1233-43.
24. World Health Organization. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Geneva, Switzerland: WHO, 2010.
25. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: amulticentre implementation study. Lancet 2011; 377:1495-505.
26. FIND Diagnostics. Negotiated prices for Xpert® MTB/RIF and FIND country list. Available at: http://www.finddiagnostics.org/about/what-we-do/successes/findnegotiated-prices/xpert-mtb-rif-with-warranty.html. Accessed 11 February 2015.
27. Qin ZZ, Pai M, Van Gemert W, Sahu S, Ghiasi M, Creswell J. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Eur Respir J 2015; 45:549-54.
28. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008; 8:15.
29. Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013; 13:690-7.
30. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO Progress Report 2011. Geneva, Switzerland: WHO, 2011.
31. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366:2161-70.
32. World Health Organization. Multidrug-resistant tuberculosis (MDR-TB) 2014 update. Geneva, Switzerland: WHO, 2014.
33. National Institute for Health and Care Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Available at: www.nice.org.uk/guidance. Accessed 27 May 2015.
34. Farley JE, Kelly AM, Reiser K, et al. Development and evaluation of a pilot nurse case management model to address multidrug-resistant tuberculosis (MDR-TB) and HIV in South Africa. PLoS One 2014; 9:e111702.
35. Weiss P, Chen W, Cook VJ, Johnston JC. Treatment outcomes from communitybased drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis 2014; 14:333.
36. Padayatchi N, Friedland G. Decentralised management of drug-resistant tuberculosis (MDR-and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis 2008; 12:978-80.
37. Cox H, Hughes J, Daniels J, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 2014; 18:441-8.
38. Loveday M, Wallengren K, Brust J, et al. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2015; 19:163-71.
39. Malla P, Kanitz EE, Akhtar M, et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One 2009; 4:e8313.
40. Cox H, Furin J, Mitnick C, Daniels C, Cox V, Goemaere E. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. BullWorld Health Organ 2015; 93:491-7.
41. Sinanovic E, Ramma L, Vassall A, et al. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis 2015; 19:172-8.
42. Basu S, Andrews JR, Poolman EM, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007; 370:1500-7.
43. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva, Switzerland: WHO, 2011.
44. Oladimeji O, Isaakidis P, Obasanya OJ, et al. Intensive-phase treatment outcomes among hospitalized multidrug-resistant tuberculosis patients: results from a nationwide cohort in Nigeria. PLoS One 2014; 9:e94393.
45. National Department of Health, South Africa. Management of drug-resistant tuberculosis: policy guidelines (updated January 2013). South Africa: National Department of Health, 2013.
46. Mor Z, Goldblatt D, Kaidar-Shwartz H, Cedar N, Rorman E, Chemtob D. Drugresistant tuberculosis in Israel: risk factors and treatment outcomes. Int J Tuberc Lung Dis 2014; 18:1195-201.
47. Médecins Sans Frontières. Scaling up diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa, 2011. Available at: http://www.msfaccess. org/sites/default/files/MSF-assets/TB/Docs/TB-report-ScalingUpDxTxKhaye- ENG-2011.pdf. Accessed 1 May 2015.
48. Shenoi SV, Escombe AR, Friedland G. Transmission of drug-susceptible and drugresistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis 2010; 50(suppl 3):S231-7.
49. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-80.
50. Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based program in Khayelitsha, South Africa. Trop Med Int Health 2015; 20:1337-45.
51. Farley JE, Tudor C, Mphahlele M, et al. A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa. Int J Tuberc Lung Dis 2012; 16:82-9.
52. Zelnick JR, Gibbs A, Loveday M, Padayatchi N, O'Donnell MR. Health-care workers' perspectives on workplace safety, infection control, and drug-resistant tuberculosis in a high-burden HIV setting. J Public Health Policy 2013; 34:388-402.
53. Engelbrecht M, van Rensburg A. Tuberculosis infection control practices in primary healthcare facilities in three districts of South Africa. South Afr J Epidemiol Infect 2013; 28:221-6.
54. Brouwer M, Coelho E, das Dores Mosse C, van Leth F. Implementation of tuberculosis infection prevention and control in Mozambican health care facilities. Int J Tuberc Lung Dis 2015; 19:44-9.
55. Brouwer M, Coelho E, Mosse C, Brondi L, Winterton L, van Leth F. Healthcare workers' challenges in the implementation of tuberculosis infection prevention and control measures in Mozambique. PLoS One 2014; 9:e114364.
56. Kanjee Z, Catterick K, Moll AP, Amico KR, Friedland GH. Tuberculosis infection control in rural South Africa: survey of knowledge, attitude and practice in hospital staff. J Hosp Infect 2011; 79:333-8.
57. Kanjee Z, Amico KR, Li F, Mbolekwa K, Moll AP, Friedland GH. Tuberculosis infection control in a high drug-resistance setting in rural South Africa: information, motivation, and behavioral skills. J Infect Public Health 2012; 5:67-81.
58. Nichol K, McGeer A, Bigelow P, O'Brien-Pallas L, Scott J, Holness DL. Behind the mask: determinants of nurse's adherence to facial protective equipment. Am J Infect Control 2013; 41:8-13.
59. Robert J, Affolabi D, Awokou F, et al. Assessment of organizational measures to prevent nosocomial tuberculosis in health facilities of 4 sub-Saharan countries in 2010. Infect Control Hosp Epidemiol 2013; 34:190-5.
60. Sissolak D, Marais F, Mehtar S. TB infection prevention and control experiences of South African nurses - a phenomenological study. BMC Public Health 2011; 11:262.
61. Woith W, Volchenkov G, Larson J. Barriers and motivators affecting tuberculosis infection control practices of Russian health care workers. Int J Tuberc Lung Dis 2012; 16:1092-6.
62. Temesgen C, Demissie M. Knowledge and practice of tuberculosis infection control among health professionals in northwest Ethiopia; 2011. BMC Health Serv Res 2014; 14:593.
63. Naidoo S, Seevnarain K, Nordstrom DL. Tuberculosis infection control in primary health clinics in eThekwini, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2012; 16:1600-4.
64. Buregyeya E, Nuwaha F, Verver S, et al. Implementation of tuberculosis infection control in health facilities in Mukono and Wakiso districts, Uganda. BMC Infect Dis 2013; 13:360.
65. Tudor C, Mphahlele M, Van der Walt M, Farley JE. Health care workers' fears associated with working in multidrug-and or extensively-resistant tuberculosis wards in South Africa. Int J Tuberc Lung Dis 2013; 17(10 suppl 1):22-9.
66. Mphahlele M, Tudor C, Farley JE. An infection control audit in 10 primary healthcare facilities in the Western Cape Province of South Africa. Int J Infect Control 2012; 8.
67. Zhou F, Zhang L, Gao L, et al. Latent tuberculosis infection and occupational protection among health care workers in two types of public hospitals in China. PLoS One 2014; 9:e104673.
68. Cox H, Escombe R, McDermid C, et al. Wind-driven roof turbines: a novel way to improve ventilation for TB infection control in health facilities. PLoS One 2012; 7: e29589.